Clinico-pathologic profile and pattern of p53 expression of lung adenocarcinoma in non-smokers and smokers in a tertiary cancer centre

Parwin Khan N. S.; Sindhu Nair P.; Renu Sukumaran; Lijeesh A. L.; Jayasree K.

doi:10.18203/2320-6012.ijrms20242212

Authors

Parwin Khan N. S. Department of Pathology, Regional Cancer Centre, Trivandrum, Kerala, India
Sindhu Nair P. Department of Pathology, Regional Cancer Centre, Trivandrum, Kerala, India
Renu Sukumaran Department of Pathology, Regional Cancer Centre, Trivandrum, Kerala, India
Lijeesh A. L. Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India
Jayasree K. Department of Pathology, Regional Cancer Centre, Trivandrum, Kerala, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242212

Keywords:

Lung adenocarcinoma, p53 expression, Smokers, Non-smokers

Abstract

Background: Lung cancer is the most common cause of cancer mortality worldwide. Smoking is undoubtedly the major risk factor of lung cancer in both genders. Adenocarcinoma is the most common form of lung cancer in both men and women and the most prevalent subtype in non-smokers. Lung cancer in never-smokers is a distinct entity with sparse studies. We studied the clinico-pathologic profile of lung adenocarcinoma and pattern of p53 expression in smokers and non-smokers.

Methods: A prospective study involving 100 lung adenocarcinoma cases from January 2020 to June 2021 examined p53 expression using immunohistochemistry. Trucut biopsies, fine needle aspiration cytology (FNAC) cell blocks, and pleural effusion were analyzed to identify the predominant morphological subtype of the lung adenocarcinoma.

Results: The most common histological pattern of lung adenocarcinoma was solid, and the presenting symptoms were cough and dyspnoea in both smokers and non-smokers. The incidence of lung adenocarcinoma was higher in non-smokers in the study. p53 expression had a significant correlation with smoking but not with stage of disease or morphological subtype of lung adenocarcinoma.

Conclusions: p53 mutation has a statistical correlation with smoking in adenocarcinomas in our population. Among the adenocarcinoma cases in our study, non-smokers predominate (n=53). Even though our study showed the p53 mutation has no statistical correlation with the stage of the disease or histological subtype in adenocarcinoma, more cases need to be studied to prove this observation.

Metrics

Metrics Loading ...

References

Kumar V, Abbas A, Fausto N. Robbbins and Cotran Pathologic Basis of Disease. 10th edition. Jeremy Bowes. 2020.

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 2015. Available at: https://publications.iarc.fr/17. Assessed on 12 May 2024.

Borczuk AC, Chan JKC, Cooper WA, Dacic S, Kerr KM, Lantuejoul S, et al. WHO Classification of Thoracic Tumours. 5th Edition. 2021. Available at: https://publications.iarc.fr/595. Assessed on 12 May 2024.

Dias M, Linhas R, Campainha S, Conde S, Barroso A. Lung cancer in neversmokers–what are the differences? Acta Oncologica. 2017;56(7):931-5.

Couraud S, Souquet P-J, Paris C, Dô P, Doubre H, Pichon E, et al. BioCAST/IFCT-1002: Epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J. 2015;45(5):1403-14.

Bryant A, Cerfolio RJ. Differences in Epidemiology, Histology, and Survival Between Cigarette Smokers and Never-Smokers Who Develop Non-small Cell Lung Cancer. Chest. 2007;132(1):185-92.

Mogi A, Kuwano H. TP53 Mutations in Nonsmall Cell Lung Cancer. J Biomed Biotechnol. 2011;583929.

Ahrendt SA, Hu Y, Buta M, McDermott MP, Benoit N, Yang SC, et al. p53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study. J Natl Cancer Inst. 2003;95(13):961-70.

el-Torky M, el-Zeky F HJ. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer. 1990;65:2361-7.

Devesa SS, Bray F, Vizcaino AP PD. International lung cancer trends by histologic type: Male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294-9.

Buccheri G, Ferrigno D. Lung cancer: Clinical presentation and specialist referral time. Eur Respir J. 2004;24(6):898-904.

Dosaka-Akita H, Shindoh M, Fujino M, Kinoshita I, Akie K, Katoh M, et al. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol. 1994;102(5):660-4.

Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 1992;52(8):2340-3.

Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992;52(17):4828-31.

Garland Lh, Beier Rl, Covlson W, Heald SR. The apparent sites of origin of carcinomas of the lung. Radiology. 1962;78:1-11.

Spencer H. Pathology of the lung. New York Pergamon Press. 1977;799.

Byers TE, Vena JE, Rzepka TF. Predilection of lung cancer for the upper lobes: An epidemiologic inquiry. J Natl Cancer Inst. 1984;72(6):1271-5.

Schlesinger Rb LM. Particle deposition in casts of the human upper tracheobronchial tree. Am Ind Hyg Assoc J. 1972;33:237-51.

Klikovits T, Lohinai Z, Fábián K, Gyulai M, Szilasi M, Varga J, et al. New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. Lung Cancer. 2018;126:139-48.

Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ, Huang BS, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258(6):1079-86.

Cha MJ, Lee HY, Lee KS, Jeong JY, Han J, Shim YM, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014;147(3):921-8.

Xu L, Tavora FB. Histologic features associated with metastatic potential in invasive adenocarcinomas of the lung. Am J Surg Pathol. 2013;37:1100-8.

Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(9):1496-504.

Zhang Y, Li J, Wang R, Li Y, Pan Y, Cai D, et al. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep. 2014;4:1-6.

Hung JJ, Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC, et al. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32(22):2357-64.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1):52-61.

Shim HS, Mari-Kenudson, Zheng Z, Liebers M, Cha YJ, Ho QH, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2015;10(8):1156-62.